Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...

Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps an Equal Weight rating on the shares.Discover the Best ...

Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.

Shares of Fortrea Holdings sank to a new low after the company said it expects revenue to drop this year. The stock fell 31% to a new all-time low of $9.55 in the first half of the trading day. The ...

The contract-research organization expects $2.45 billion to $2.55 billion in revenue for 2025, down from $2.7 billion last year. Analysts polled by FactSet had been forecasting a small gain to $2.73 ...